Ceritinib following crizotinib relapse for ALK positive NSCLC

Atezolizumab v docetaxel for NSCLC: results from the OAK trial

Significant survival gains with atezolizumab for NSCLC

Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression

Pembrolizumab plus chemo as firstline therapy for NSCLC

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients

Firstline pembrolizumab plus chemo improves NSCLC outcomes

KRAS in the clinic and conference

A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)

Thousands of melanoma patients in Europe have no access to new drugs

Phase I results of a novel FGFR inhibitor